The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. by Turley, H. et al.
British Joumal ofCancer(1997) 75(9), 1340-1346
© 1997 Cancer Research Campaign
The distribution and expression of the two isoforms of
DNA topoisomerase 11 in normal and neoplastic human
tissues
H Turley', M Comley', S Houlbrook2, N Nozaki3, A Kikuchi3, ID Hickson2, K Gatter' and AL Harris2
Department of 'Cellular Science and 2Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK;
3Mitsubishi Kasei Institute of Sciences, 11 Minamiooya, Machida 194, Japan
Summary In mammalian cells, there are two isoforms of DNA topoisomerase 11, designated a (170-kDa form) and ,B (180-kDa form).
Previous studies using cell lines have shown that the topoisomerase Ila and [ isoforms are differentially regulated during the cell cycle and in
response to changes in growth state. Moreover, both isoforms can act as targets for a range of anti-tumour drugs. Here, we have analysed
the normal tissue distribution in humans oftopoisomerase Ila and f using isoform-specific antibodies. In addition, we have studied expression
of these isoforms in 69 primary tumour biopsies, representative either of tumours that are responsive to topoisomerase 11-targeting drugs
(breast, lung, lymphoma and seminoma) or of those that show de novo drug resistance (colon). Topoisomerase lla was expressed exclusively
in the proliferating compartments of all normal tissues, and was detectable in both the cell nucleus and cytoplasm. In biologically aggressive
or rapidly proliferating tumours (e.g. high-grade lymphomas and seminomas), there was a high level of topoisomerase Ila, although
expression was still detectable in colon tumours, indicating that expression of this isoform is not sufficient to explain the intrinsic drug
resistance of colon tumours. Topoisomerase Ill was expressed ubiquitously in vivo and was localized in both the nucleoli and the
nucleoplasm. This isoform was present in quiescent cell populations, but was expressed at a generally higher level in all tumours and
proliferating cells than in normal quiescent tissues. We conclude that topoisomerase Ila is a strict proliferation marker in normal and
neoplastic cells in vivo, but that topoisomerase ll[ has a much more general cell and tissue distribution than has topoisomerase Ila. The
apparent up-regulation of topoisomerase II,B in neoplastic cells has implications for the response of patients to anti-tumour therapies that
include topoisomerase Il-targeting drugs.
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Topoisomerase II is a homodimeric nuclear protein with many
different roles in DNA metabolism, including relief of torsional
stress and mitotic chromosome condensation and segregation
(reviewed in Wang, 1985, 1991; Watt and Hickson, 1994). Topo-
isomerase II is also one of the most important determinants of
cellular sensitivity to a range of clinically important anti-tumour
drugs. For example, topoisomerase II is the primary cellular target
for several intercalating agents, including doxorubicin, mitox-
antrone and epirubicin, as well as for the non-intercalating
epipodophyllotoxins, etoposide and teniposide (reviewed in
Osheroff et al, 1991; Pommier, 1993; Beck et al, 1993). Topo-
isomerase II is a so-called type II enzyme, defined as acting via the
creation ofdouble-stranded breaks in DNA, through which an intact
DNA duplex is passed, before the break is resealed. As part ofthis
breakage and religation process, a transient reaction intermediate is
generated, termed the cleavage complex, consisting of a topoiso-
merase II dimerbound covalently to the 5'phosphoryl groups ofthe
cleaved DNA (Osheroff et al, 1991). It is at the cleavable complex
stage that topoisomerase II-targeting drugs have their primary
effect, as a result of inhibiting DNA strand break religation. As a
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consequence, cells treated with topoisomerase II inhibitors accumu-
late DNA strand breaks bound covalently by topoisomerase II
protein. These breaks lead ultimately to cell death via an apoptotic
pathway, although the details of the downstream signalling from
cleavable complexes to cell death are poorly understood.
Cellular responses to topoisomerase II-targeting drugs depend,
at least in part, on the expression level of the target enzyme. High
topoisomerase II protein levels confer relative drug sensitivity
(Davies et al, 1988; Fry et al, 1991), while low levels confer resis-
tance (reviewed in Pommier, 1993; Beck et al, 1993). Although
topoisomerase II is well established as a key nuclear target for
cytotoxic drugs, it is not clear which of the two known isoforms
(Tsai-Pflugfelder et al, 1988; Tan et al, 1992; Jenkins et al, 1992;
Austin et al, 1993) expressed in human cells, which are designated
topoisomerase Ila and [, is the primary cellular drug target.
Indeed, it may be the case either that both isoforms are targets or
that different classes of topoisomerase inhibitors preferentially
target one or other isozyme.
Topoisomerase II protein expression is regulatedby theprolifer-
ation status ofcell lines. Topoisomerase IIo is absent from conflu-
ence-arrested cells or those deprived of serum, and this isoform
apparently only accumulates to high levels during the G2 and M-
phases ofthe cell cycle (Woessner etal, 1991; Prosperi etal, 1994;
Isaacs et al, 1996). In contrast, topoisomerase Ilp is expressed in
cycling and non-cycling cell lines (Woessner et al, 1991).
Although topoisomerase II[ does not appear to be regulated
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during the transition from proliferation to quiescence in vitro, data
derived from studies on human lymphocytes indicate that topoiso-
merase II[ may be regulated in vivo by the proliferation status of
cells (Kaufmann et al, 1994). The ability of topoisomerase II-
targeting drugs to kill cell lines in vitro is also strongly dependent
upon cell proliferation, with quiescent cells showing an enhanced
level of drug resistance (Osheroff et al, 1991; Pommier, 1993;
Beck et al, 1993). It is important to know, therefore, whether the
topoisomerase Ila and [ isoforms are differentially expressed
and/or regulated in vivo. Here, we have studied the normal tissue
distribution in humans of the topoisomerase Ila and [B proteins
using isoform-specific monoclonal antibodies. In addition, we
have analysed representative samples of malignant cells from
tumour types in which topoisomerase II inhibitors are routinely
used therapeutically. We show that, although topoisomerase IIa is
a strict proliferation marker in vivo, topoisomerase 11, is
expressed widely and in all tissue types, including within quies-
cent cell compartments. In contrast to some previous reports, we
find that topoisomerase II is detectable both in the nucleoplasm
and in nucleoli, and is expressed at a generally higher level in
neoplastic than in normal tissues.
MATERIALS AND METHODS
Growth and immunocytochemical analysis of cell lines
Cell lines were grown in RPMI-1640 medium (Gibco-BRL)
supplemented with 10% fetal bovine serum, 4 mm glutamine and
antibiotics in a humidified atmosphere containing 5% carbon
dioxide at 370C. For immunocytochemical staining, cytospin
samples were prepared on glass slides using a Shandon cytocen-
trifuge. The cytospin samples were then air dried and fixed in
phosphate-buffered saline (PBS) containing 3.7% formalin for 15
min before immunostaining. The cell lines used were as follows:
SUDHL-1 (T-cell lymphoma), MCF-7 (breast carcinoma), SuSa
(testicular teratoma), NC1460 (non-small-cell lung cancer) and
CEM (erythroleukaemia).
Table Staining of human tumours for topoisomerase Ila expression
No. of cases Nuclear positive (%)
Tumourtype (n) <5 5-30 >30-60 >60
Lymphomas
High-grade NHL 4 - 1 1 2
Low-grade NHL 7 - 6 1 -
CLL 8 6 1 1 -
Hodgkin's disease 10 2 7 1 -
Lung
Squamous 7 - 4 3 -
Adenocarcinoma 4 2 2 - -
Carcinoid 1 1 -
Small cell 1 - - 1 -
Seminoma 8 - - 5 3
Colon 10 - - 8 2
Breast 9 8 1 - -
Total 69 19 22 21 7
Tumours are classified by type and percentage of nuclei staining for
topoisomerase Ila. NHL, non-Hodgkin's lymphoma.
Antibodies
The CRB antibody was raised in rabbits to an extreme C-terminal
peptide ofthe human topoisomerase IlIaprotein (Arg-Ala-Lys-Lys-
Pro-Ile-Lys-Tyr-Leu -Glu-Glu-Ser-Asp-Glu-Asp-Asp-Leu-Phe)
and was suppliedby Cambridge ResearchBiochemicals (UK). This
antibody has been validated in previous studies (Smith and
Makinson, 1989; Wells et al, 1994). The generation of the 3H10
antibody specific for topoisomerase 11, will be described in detail
elsewhere (N Nozaki et al, manuscript in preparation). Briefly, a
peptide encompassing residues 1583-1601 (SDFPTEPPSLPRT-
GRARKE) of the deduced human topoisomerase IlI sequence
(Jenkins et al, 1992) was synthesized, conjugated to keyhole limpet
haemocyanin, and was injected four times every 2 weeks into a
Balb/c mouse. Antibody-secreting cells were screened using a
partially purified preparation oftopoisomerase II from HL60 cells.
The hybridoma 3H10 was cloned and shown to secrete antibody of
theIgG2a subtype.
Western blotting
Whole-cell extracts from the human lung carcinoma cell line
NCI460 and an etoposide-resistant derivative, designated
NC1460/pV8, were prepared for Western blotting by lysing cells
directly in sodium dodecyl sulphate (SDS) sample buffer (200 jg
protein ml-') before separation on a 7% SDS-polyacrylamide gel
(Laemmli, 1970). Proteins were then electroblotted at 30 volumes
for 16 h onto Hybond-ECL nitrocellulose (Amersham). Detection
of topoisomerase Ilc and [ was performed using the CRB anti-
body (topoisomerase IHa-specific) at 1:1000 dilution and the 3H10
antibody (topoisomerase Il1f-specific) at 1:5 dilution. Enhanced
chemiluminescence detection was as recommended by the
supplier (Amersham), with the blocking buffer comprising 20 mm
Tris-HCl, pH 7.6, 0.9% sodium chloride, 0.05% Tween 20 and 1%
low-fat milk powder.
Tissues
A range ofnormal tissues (tonsil, spleen, lymph node, thymus, skin,
pancreas, testis, colon, kidney, liver, brain and lung) and tumours
[nine breast carcinomas, ten colon carcinomas, 13 lung carcinomas,
ten cases of Hodgkin's disease, 13 large-cell non-Hodgkin's
lymphomas (NHL), eight cases of lymphocytic lymphoma (CLL)
and eight seminomas ofthe testis; see the Table] was obtained from
the frozen tissue bank stored at-70°C in the University Department
ofCellular Science, John Radcliffe Hospital, Oxford, UK. Cryostat
sections of 8 mm were obtained and were mounted on poly-L-
lysine-coated glass slides. After drying for between 30 min and 8 h,
the sections were fixed in PBS containing 3.7% formalin for 15 min
and then immediately immunostained using an immunoperoxidase
Duet kit (Dako, Denmark).
The tumours were classified according to the proportion of
labelled cell nuclei as follows: 0-5%, 5-30%, 30-60% and more
than 60%. These were established initially by counting the number
of unlabelled and labelled nuclei throughout the section. It was
found with experience that this system could be reproduced
without formal counting by visual inspection of the section. This
was validated by reviewing tumours in the series and comparing
visual estimates with the previously established percentages.
Tumours were consistently placed within the same proliferation
category.
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Figure 1 The CRB and 3H10 antisera detect 170-kDa and 180-kDa proteins,
respectively, in human cell nuclear extracts. A 0.35 M sodium chloride nuclear
protein extract prepared from NC1460 cells (lanes 2 and 4) or NC1460/pV8
cells (lanes 1 and 3) was electrophoresed alongside molecular weight
standards on a 9% SDS-polyacrylamide gel, transferred to Hybond-N, and
the membrane was exposed either to the CRB antiserum (lanes 1 and 2) or
to a mixture of the CRB and 3H10 antisera (lanes 3 and 4). Antibody
detection was the ECL system. Molecular weights (in kDa) are indicated on
the left. The positions of the 170-kDa topoisomerase lla and the 180-kDa
topoisomerase lip protein are indicated on the right
RESULTS
Characterization of topoisomerase 11 isoform-specific
antibodies
Western blotting with the CRB antibody raised to a synthetic
peptide from the topoisomerase IIh protein sequence (that is not
conserved in topoisomerase II) revealed a single 170-kDa
immunoreactive protein consistent with the known size of the
topoisomerase Ila protein (Figure 1). This antibody has been
shown in previous studies to be specific for the topoisomerase lloz
isoform (Smith and Makinson, 1989; Wells et al, 1994). When the
CRB and the 3H10 (which was raised to a non-conserved peptide
from the topoisomerase IlI sequence) antibodies were mixed and
the same filter was exposed simultaneously to both antibodies, a
second 180-kDa immunoreactive protein of the size of topoiso-
merase Ilf was revealed (Figure 1). Western blots using the 3H10
antibody alone revealed a single immunoreactive protein of
180 kDa, which co-migrated with topoisomerase IIp protein
detected with a previously characterized (Houlbrook et al, 1995)
rabbit polyclonal anti-topoisomerase II3 antiserum raised against
recombinant protein (data not shown). Thus, we conclude that the
CRB and 3H10 antibodies are specific for the oc and D isoforms of
topoisomerase II respectively.
Normal tissue distribution of topoisomerase 1I1a and D in
humans
Topoisomerase Ila
The anti-topoisomerase Ia peptide antiserum, CRB, produced
nuclear staining in all ofthe normal tissues studied with a distribu-
tion very similar to that seen with known proliferation-associated
antigens, such as Ki-67 (Figure 2). For example, in lymphoid
tissue, topoisomerase II-expressing cells were numerous in the
germinal centres, but scarce in mantle zones. In epithelium and
testicular tubules, positive staining for topoisomerase IIa was
present in the basal layers, but not in the more mature superficial
cells. In colon and lung, positive staining was present in a minority
of basal and alveolar epithelial cells respectively. In other tissues,
including liver, kidney and brain in which the majority ofthe cells
are mature and non-proliferating, positive staining was limited to a
few scattered cells. Cytoplasmic staining was noted in some
tissues, and was found in the same cell populations in which
nuclear staining was evident.
Topoisomerase 11p
The anti-topoisomerase Ilf peptide 3H10 antiserum produced
positive staining in virtually all cell nuclei within all of the normal
tissues studied (Figure 2). A punctate pattern of nuclear staining
was evident, which was localized both within nucleoli and
dispersed throughout the nucleoplasm. In areas representing
proliferating cell populations, such as lymphoid germinal centres,
the nucleoli appeared larger, and there was a greater dispersion of
immunoreactive material into the surrounding nucleoplasm. In
colon there were scattered nuclear dots in most of the cells.
Expression of topoisomerase lhex and D in neoplastic
tissues
Topoisomerase Ila
The staining pattern fortopoisomerase IIo protein seen in the range
of tumours examined reflected that of the normal tissues described
above. The CRB antibody gave a pattern of nuclear staining that
strongly correlated with that seen with antibodies to the established
proliferation marker, Ki-67 antigen. Of particular note was the
striking positivity ofthe abnormal mono- and multinucleate cells in
cases of Hodgkin's disease (Figure 2). Cytoplasmic staining with
the CRB antibody was noted and was generally more evident in the
tumour biopsies than it was in the normal tissue samples.
The proportion of tumour cells staining positive for topoiso-
merase 11o ranged from less than 5% to more than 60%, and this
was related to tumour type and grade (Figure 2 and the Table). For
example, high-grade lymphomas had a higher proportion of posi-
tively staining cells than did low-grade lymphomas and lymph
nodes from patients with chronic lymphatic leukaemia. For non-
small-cell lung cancers, the squamous tumours had a higher
proportion ofpositively staining cells than did adenocarcinomas or
carcinoid tumours. Seminomas showed the highest percentage of
cells staining positive for topoisomerase Ila, while expression was
generally low in breast cancers. The intrinsically drug-resistant
colon tumours analysed showed a generally high percentage of
cells staining positive for topoisomerase IIo (Table).
Topoisomerase 11/3
The topoisomerase IlI-specific antibody 3H10 produced granular
nuclear staining in virtually all of the cell types in every tumour
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Figure 2 Staining of tissues for topoisomerase Ila and f. Left-hand pictures are stained for topoisomerase a (A, C, E and G). Right-hand pictures are stained
for topoisomerase 5 (B, D, F and H). A and B show tonsil sections at low power and C and D are tonsil sections at higher power. Topoisomerase a (A and C) is
mainly restricted to the larger cells in the germinal centre (centroblasts), whereas topoisomerase ,B (B and D) is very widely distributed in all cell types, including
the B- and T-cell areas. E and F show sections of a squamous cell carcinoma of the lung, and G and H show a case of Hodgkin's disease. The distribution of
topoisomerase lla staining is similar to that seen with anti-proliferation-associated antibodies (such as Ki-67), whereas topoisomerase f3 is found in the majority
of cell types, including Reed-Sternberg cells in Hodgkin's disease (H)





Figure 3 Expression of topoisomerase Ila and ,B in cytospin preparations of the SUDHL-1 cell line using immunoperoxidase staining. (A and C) Localization of
topoisomerase , in SUDHL-1 stained with antibody 3H10. The antigen is present as granular spots in the interphase nucleus, but during mitosis the antigen is
absent from the nucleus and present as spots in the cytoplasm. (B and D) Localization of topoisomerase lla using the CRB antibody. The antigen is present on
the whole of the nucleus with stronger staining in nucleolar areas (cells in mitosis show antigen associated with condensed chromatin, not in the cytoplasm)
analysed. No direct association withproliferative index (and there-
fore with topoisomerase Ila expression) was evident, although
there was a generally higher intensity of staining in tumour tissue
than that seen in normal tissues (Figure 2). In each tumour sample,
a minimum of 50% of the cells stained positive for topoisomerase
11, although in most cases more than 90% of cells expressed
topoisomerase II. As with normal tissues, staining within both
nucleoli and in the nucleoplasm was evident with the 3H10 anti-
body, but more intense staining coincided with nucleolar struc-
tures. In lymphoid neoplasms, only a limited amount of
cytoplasmic staining was evident, but in the seminomas and
epithelial neoplasms (lung colon and breast cancer), many cells
had a low level ofdetectable cytoplasmic staining.
Expression of topoisomerase lla and 1B in cell lines
Topoisomerase Ila
Staining of cell lines with the CRB antibody showed nuclear
staining with nucleolar accentuation. The mitotic figures were
strongly positive (Figure 3). There was some cytoplasmic staining,
but this was weak.
Topoisomerase Il,B
Staining with 3H10 on all of the lines showed a different pattern
from that ofCRB. The pattern was nuclear, but showed a granular
distribution (Figure 3). In one cell line (SUDHL-1), the cells
undergoing mitosis (or cells that hadjustdivided) showed staining
in the cytoplasm as granules with a negatively staining nucleus.
DISCUSSION
We have analysed the expression and distribution of the cc and 1
isoforms oftopoisomerase 11 in normal and neoplastic human tissues.
Topoisomerase Hla was detected in the proliferative compartment of
all normal tissues, as would be expected for an enzyme with a cell
division-specificrole, suchasmitotic chromosomesegregation and/or
condensation. In contrast, topoisomerase 13 was detectable in virtu-
ally all cells, irrespective oftheir proliferative status, although some
evidence formodestup-regulation inproliferating cells was obtained.
A number of previous reports have analysed the expression of
topoisomerase II enzymes in a selection of normal tissues and
tumours. For example, Holden et al (1994) reported that topoiso-
merase IIac was expressed at the base ofsmall intestinal glands and
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in the germinal centres oftonsil tissue, consistent with a prolifera-
tion-specific pattern of expression (Woessner et al, 1991) and in
agreement with our data using a different antibody to topoiso-
merase Iloc. Moreover, we and others have previously studied
topoisomerase Ila expression in some tumour types (Tuccari et al,
1993; Kaufmann et al, 1994; Holden et al, 1994; Hellemans et al,
1995; Sandri et al, 1996), and it has been suggested that high levels
of protein expression may be associated with histological and
cytological features of high grade, poor differentiation or high
proliferation (Tuccari et al, 1993; Kaufmann et al, 1994;
Hellemans, et al, 1995; Sandri et al, 1996).
In the present study, expression oftopoisomerase Ila was exam-
ined both in tumours known to be responsive to topoisomerase II-
targeting drugs and in those that display de novo drug resistance.
A high level of expression was seen in those tumours known to
have a high proliferative index (e.g. seminomas and high-grade
non-Hodgkin's lymphomas). While it has been suggested that
expression of topoisomerase II isoforms may be responsible for
the drug responsiveness ofcertain tumour types, it is clear that the
lack of response to chemotherapy typically seen in colon tumours
treated with topoisomerase 11-targeting drugs is not caused by a
lack of the target enzyme. Indeed, some of the colon tumours
displayed high levels ofexpression ofboth topoisomerase IIa and
P. This indicates that the inherent drug resistance ofcolon cancers
is probably related to factors other than topoisomerase II expres-
sion, such as drug uptake or the ability to induce apoptosis after
DNA damage. It would be interesting to analyse the relationship
between DNA damage and cell death in these tumours.
Topoisomerase Ila was detected in the cytoplasm of cell lines,
normal tissues and tumours. This was seen in both frozen and
paraffin-embedded tissue sections. Moreover, we have detected
cytoplasmic staining for topoisomerase Ila using a second anti-
body raised to a different peptide from within the topoisomerase
Ila sequence (unpublished observation). This cytoplasmic local-
ization for topoisomerase IIo has not been described previously in
human tissues, but a variation in intracellular distribution during
the different phases of the cell cycle has been described for topo-
isomerase II in Drosophila cells (Swedlow et al, 1993). The role of
the cytoplasmic fraction of topoisomerase Ila is not clear at this
stage. It is possible that topoisomerase 11o requires phosphoryla-
tion for nuclear localization, as has been reported for p53 and
several other proteins (reviewed in Jans, 1995). We, and others,
have demonstrated that human topoisomerase Ila is aphosphopro-
tein and requires phosphorylation for its activation (Kroll and
Rowe, 1991; Wells et al, 1994; Wells and Hickson, 1995; Wells et
al, 1995). The cytoplasmic fraction of topoisomerase Ila protein
may act as a reservoir of inactive enzyme that can be simultane-
ously activated and translocated to the nucleus as and when
required. The existence ofacytoplasmic fraction oftopoisomerase
Ila also implies that the use of Western blotting of whole cell
extracts to quantify topoisomerase IIoc protein levels may take into
account a fraction of the protein pool that is not localized at its
primary site ofaction and may, therefore, not be functional.
Topoisomerase II has previously been shown to be expressed
in quiescent cells in vitro and during all phases of the cell cycle
(Woessner et al, 1991). Consistent with this, we observed positive
staining for topoisomerase I13 in virtually all cells in all tissues
and tumours. Previous studies using antibodies that recognise a
150-kDa protein, presumed to be a breakdown product oftopoiso-
merase 1I, have suggested that this isoform is localized exclus-
ively to nucleoli (Zini et al, 1992). Using those antibodies,
D'Andrea et al (1994) studied expression of the 150-kDa antigen
in melanoma and lung cancer and observed a poor correlation of
the expression ofthis protein with proliferation. In our study, using
the 3H10 antibody that exclusively recognizes a 180-kDa protein
on Western blots, topoisomerase I1I was found in both nucleoli
and the nucleoplasm, in agreement with the findings ofPetrov et al
(1993). Indeed, using the 3H10 antibody and a second rabbit poly-
clonal antibody to topoisomerase II (Houlbrook et al, 1995), we
have not detected a 150-kDa cross-reacting protein on Western
blots, and therefore the identity of the previously described
150-kDa protein is not clear at this stage. Because different anti-
bodies may have different affinities for their cognate epitopes and
the latter may differ in numbers per molecule, it is not possible to
compare directly between topoisomerase 11f3 and topoisomerase
Ilo levels by immunohistochemistry.
The widespread expression of topoisomerase I1I in normal,
non-proliferating tissues implies that this isoform may undertake
an important function in quiescent cells. However, it should be
noted that the striking down-regulation of topoisomerase II that
has been described in certain drug-resistant cell lines (Osheroff et
al, 1991; Pommier, 1993; Beck et al, 1993) possibly indicates that
topoisomerase 111 is dispensable for cell division in transformed
cell lines in vitro. Our results showing absence of topoisomerase
11I from the nucleus ofSUDHL-1 cells during mitosis support this
hypothesis. Localization of topoisomerase II in the nucleolus, as
well as in the nucleoplasm, could be related to a role in some
aspect of ribosomal, as well as general, gene expression. Many of
the foci of staining within the nucleoplasm appeared to coincide
with the most intense general DNA staining using DAPI (data not
shown). Further work will be required to confirm whether or not
this co-localization reflects an interaction of topoisomerase II1
with heterochromatin.
In all of the chemoresponsive tumours studied, there was a
higher level of expression of topoisomerase II than in normal
quiescenttissues. Moreover, the intensity ofstaining was consider-
ably higher in the tumour tissue than in the proliferating compart-
ment of the normal tissue from which the tumour arose. The
proportion of tumour cells expressing topoisomerase II at this
elevated level was always greater than the proportion of tumour
cells that expressed detectable topoisomerase 1Ia protein, indi-
cating that proliferation alone is unlikely to be the basis ofthis up-
regulation of topoisomerase II in many of these tumours. Taken
together, these data raise the possibility that the major target for
topoisomerase TI-targeting drugs in many human cancers may be
topoisomerase 13, and nottopoisomerase I1o as has been assumed
hitherto. The observation that topoisomerase IP: is frequently up-
regulated in certain human cancers indicates that this isoform
should be evaluated further as a potential target for the develop-
ment ofnew anti-tumour agents.
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